Welcome to our dedicated page for Tenet Healthcare SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Tenet Healthcare Corporation (NYSE: THC) brings together the company’s official regulatory disclosures, offering a structured view of how this diversified healthcare services organization reports its activities in the general medical and surgical hospitals industry. As a Nevada-incorporated public company with common stock and certain senior notes listed on the New York Stock Exchange, Tenet files a range of documents with the U.S. Securities and Exchange Commission.
Key filings include Form 8-K current reports that describe material events such as quarterly earnings releases, new credit agreements, amendments to letter of credit facilities, and issuances of senior secured first lien notes and senior notes. These filings explain how Tenet structures its debt, the terms of its revolving credit facility and borrowing base, and the use of proceeds from note offerings to redeem or partially redeem existing notes. 8-K reports also cover governance matters like director resignations and adjustments to board size.
Investors can also use this page to access periodic reports such as annual and quarterly filings when available, which provide segment information for the Ambulatory business (United Surgical Partners International) and the Hospital Operations and Services segment, as well as details on Conifer Health Solutions’ revenue cycle and value-based care services. These documents help clarify how Tenet’s hospital, ambulatory and services operations are reflected in its financial statements and risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, such as new debt issuances, covenant terms, or changes in financial outlook. Real-time updates from EDGAR, combined with simplified explanations of complex credit agreements and note indentures, allow users to quickly understand how new filings may relate to Tenet’s capital structure, liquidity, and operational focus.
Tenet Healthcare Corporation issued new senior notes to refinance existing debt. The company sold $1,500,000,000 of 5.500% senior secured first lien notes due 2032 and $750,000,000 of 6.000% senior notes due 2033. Tenet plans to use the net proceeds, together with cash on hand, to redeem all $1.5 billion of its 6.250% senior secured second lien notes due February 2027 and to partially redeem $0.75 billion of its 6.125% senior notes due October 2028.
The new indentures include covenants that limit certain activities like incurring liens, entering sale and lease-back transactions, and major asset sales, but they allow Tenet and its subsidiaries to incur additional indebtedness and make dividends or other distributions. The notes may be redeemed by Tenet before or after November 15, 2028 at specified prices, including make-whole premiums if redeemed early.
Tenet Healthcare (THC): Insider stock sale disclosed. Principal Accounting Officer R. Scott Ramsey reported open-market sales of common stock on 11/06/2025. Transactions included 8,056 shares at a weighted average price of $204.75 (sold across $204.21–$205.13) and 5,066 shares at a weighted average price of $205.62 (sold across $205.21–$206.14), plus 200 shares at $206.51. After these sales, the table shows beneficial ownership of common stock at 0 shares. The filing lists transaction code “S” for sales and notes weighted-average pricing with details available upon request.
Tenet Healthcare (THC) director Tammy Romo reported an open market sale of company stock. On 11/05/2025, she sold 645 shares of common stock at $205.20 per share, according to a Form 4 insider filing. After this transaction, she directly owns 34,866 shares of Tenet Healthcare common stock.
Tenet Healthcare (THC) filed a Form 144 indicating an intended sale of 13,322 shares of common stock through Fidelity Brokerage Services LLC on or about 11/06/2025, to be sold on the NYSE. The filing lists an aggregate market value of $2,732,412.25 for the proposed sale.
The shares reflect restricted stock that vested on multiple dates and were received as compensation from the issuer. Shares outstanding were 87,885,000; this is a baseline figure, not the amount being sold.
Tenet Healthcare (THC) director Tammy Romo reported open‑market sales of 26,855 shares on November 3–4, 2025. Trades occurred in multiple transactions within a per‑share range of $200.00 to $204.93, with weighted‑average prices disclosed for each tranche.
Following these transactions, Romo beneficially owns 35,511 shares, held directly. The filing lists tranches of 8,654, 5,945, 500, 11,410 and 346 shares at weighted‑average prices of $200.43, $201.23, $202.27, $204.04 and $204.93, respectively.
Tenet Healthcare Corporation entered a new senior secured asset‑based revolving credit facility of up to $1.9 billion, including a $200 million sub‑facility for letters of credit. Borrowing availability is tied to a borrowing base of eligible accounts receivable, inventory and Medicaid supplemental payments. The facility is guaranteed by certain domestic wholly owned hospital subsidiaries and secured by a first‑priority lien on accounts receivable and inventory.
Loans bear interest at a base rate plus 0.25%–0.50% or SOFR/EURIBOR plus 1.25%–1.50%, with a 0.25% commitment fee on undrawn commitments. It terminates on November 4, 2030 or earlier upon specified springing maturities tied to certain senior notes, subject to stated conditions. Tenet also amended and extended its separate $200 million letter of credit facility to November 4, 2030, with an unused fee of 0.25% and a 1.25% fee on issued but undrawn letters; unreimbursed drawings accrue at base rate plus 0.25%.
Tenet Healthcare (THC): Tammy N. Romo filed a Form 144 notice to sell up to 645 shares of Common stock, with an aggregate market value of $132,350.78. The planned sale is listed for 11/05/2025 on the NYSE via Fidelity Brokerage Services LLC.
The 645 shares were acquired on 05/08/2018 through restricted stock vesting as compensation. Recent sales by this holder during the past three months include 15,099 shares on 11/03/2025 for gross proceeds of
Shares outstanding are 87,885,000. This notice reflects a proposed sale under Rule 144; proceeds relate to the selling holder’s transactions.
Tenet Healthcare (THC): Form 144 notice of proposed sale
A holder of Tenet Healthcare common stock filed a Form 144 to sell up to 11,756 shares of common stock, with an aggregate market value of $2,399,032.11. The proposed sale is noted for 11/04/2025 on the NYSE through Fidelity Brokerage Services LLC.
Tenet Healthcare had 87,885,000 shares outstanding. The shares to be sold were acquired via restricted stock vesting in two tranches: 939 shares on 05/04/2021 and 10,817 shares on 05/03/2022. In the past three months, a sale of 15,099 shares on 11/03/2025 generated gross proceeds of $3,031,952.87.
Tenet Healthcare (THC) announced private offerings of $1.5 billion of 5.500% senior secured first lien notes due 2032 and an upsized $0.75 billion of 6.000% senior notes due 2033, with closings expected on November 18, 2025, subject to customary conditions. The first lien notes will be guaranteed by certain subsidiaries and secured on a first-lien basis; the senior notes are unsecured and rank pari passu with Tenet’s existing senior unsecured obligations.
The company plans to use net proceeds, together with cash on hand, to redeem all $1.5 billion of its 6.250% senior secured second lien notes due February 2027 and to partially redeem $0.75 billion of its 6.125% senior notes due October 2028. Tenet issued conditional redemption notices for both series, with redemptions scheduled for November 19, 2025. The transaction shifts maturities to 2032/2033 and lowers stated coupons on the refinanced debt.
Form 144 filed for a proposed sale of 15,099 common shares. The notice lists an aggregate market value of $3,031,952.87, with an approximate sale date of 11/03/2025. The broker is Fidelity Brokerage Services LLC, and the shares are listed on the NYSE.
The shares to be sold were acquired through restricted stock vesting: 11,139 shares on 05/29/2023 and 3,960 shares on 05/07/2024, recorded as compensation. The table also notes 87,885,000 shares outstanding; this is a baseline figure, not the amount being sold.